Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

Dosage of statin drugs given to patients with heart disease should be monitored: Study

The type and dosage of statin drugs given to patients to treat heart disease should be proactively monitored as they can have unintended adverse effects, concludes a new study published on bmj.com.

27 May 2010

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

The incidence of rheumatoid arthritis (RA) in women has risen during the period of 1995 to 2007, according to a newly published study by researchers from the Mayo Clinic. This rise in RA follows a 4-decade period of decline and study authors speculate environmental factors such as cigarette smoking, vitamin D deficiency, and lower dose synthetic estrogens in oral contraceptives may be the source of the increase.

27 May 2010

Drug and dosage influence risk of GI bleeding

A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.

27 May 2010

Logical Therapeutics closes $16.9 million Series C equity financing round

Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing. The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

27 May 2010

FDA accepts Horizon Pharma's DUEXA NDA for review

Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.

27 May 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

Study finds disagreement between RA patients and doctors on assessment of disease severity

A novel study by researchers at the University of California, San Francisco found that nearly one-third of Rheumatoid Arthritis (RA) patients differed from their physicians in assessment of their disease severity. The disagreement between patient and doctor evaluation of RA activity was most prevalent in patients with depressive symptoms, and those who had poor overall function.

26 May 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the receipt of $5 million from Nycomed for reaching a clinical milestone under the license and collaboration agreement, entered into on July 11, 2008.

26 May 2010

Exactech acquires Brighton Partners

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has acquired Brighton Partners, Inc., the sole source supplier of the direct compression molded polyethylene bearings used exclusively in Exactech's flagship product, the Optetrak® knee replacement system.

25 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Rush University Medical Center uses Mini TightRope procedure to treat bunions

A less invasive, surgical treatment for bunions known as the Mini TightRope procedure is being used at Rush University Medical Center to correct bunions, or hallux valgus, a common, often painful deformity in which the big toe is angled in toward the smaller toes.

25 May 2010

Researchers develop new therapy for psychological treatment of patients suffering from fibromyalgia

Researchers of the Labpsictec at the Universitat Jaume I of Castellon and the LahHuman Group at the Universidad Politecnica of Valencia and the University of Valencia have developed a new therapy based on the use of mobile devices and virtual reality for the psychological treatment of patients suffering from fibromyalgia.

24 May 2010

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Current research suggests that T helper-type 1 (Th1) cells, previously thought to mediate autoimmunity, may actual inhibit the development of experimental immune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), by suppressing Th17 cells.

24 May 2010

High family medical bills appear to reduce use of expensive medications: Study

People with rheumatoid arthritis whose health insurance requires them to pay a higher share of the cost are less likely to use biotech drugs than those with coverage that is more generous. High family medical bills also appear to reduce the use of these powerful but expensive medications, according to a new study in Health Services Research.

21 May 2010

Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program

Ligand Pharmaceuticals Incorporated announced today that it has purchased from the Genaera Liquidating Trust certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune. MEDI-528 is currently in a 320-patient Phase II study for moderate-to-severe asthma.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Amgen announces European approval of Prolia

Dosage of statin drugs given to patients with heart disease should be monitored: Study

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

Drug and dosage influence risk of GI bleeding

Logical Therapeutics closes $16.9 million Series C equity financing round

FDA accepts Horizon Pharma's DUEXA NDA for review

VisEn Medical announces launch of two new imaging agents at EMIM 2010

Study finds disagreement between RA patients and doctors on assessment of disease severity

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Exactech acquires Brighton Partners

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Rush University Medical Center uses Mini TightRope procedure to treat bunions

Researchers develop new therapy for psychological treatment of patients suffering from fibromyalgia

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

High family medical bills appear to reduce use of expensive medications: Study

Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program

Cancer Institute of New Jersey investigators target autophagy

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in